Sign In
Buy COGZF
Cogstate Earnings Calls
| Release date | Feb 18, 2026 |
| EPS estimate | $0.0210 |
| EPS actual | $0.0256 |
| EPS Surprise | 21.90% |
| Revenue estimate | 26.9M |
| Revenue actual | 26.92M |
| Revenue Surprise | 0.0743% |
| Release date | Aug 17, 2025 |
| EPS estimate | - |
| EPS actual | $0.0370 |
| Revenue estimate | 29.1M |
| Revenue actual | 30.009M |
| Revenue Surprise | 3.13% |
| Release date | Feb 20, 2025 |
| EPS estimate | - |
| EPS actual | $0.0224 |
| Revenue estimate | 23.9M |
| Revenue actual | 23.944M |
| Revenue Surprise | 0.186% |
| Release date | Aug 21, 2024 |
| EPS estimate | - |
| EPS actual | $0.0200 |
| Revenue estimate | 22M |
| Revenue actual | 23.25M |
| Revenue Surprise | 5.68% |
Last 4 Quarters for Cogstate
Below you can see how COGZF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 21, 2024 |
| Price on release | $0.764 |
| EPS estimate | - |
| EPS actual | $0.0200 |
| Date | Price |
|---|---|
| Aug 15, 2024 | $0.81 |
| Aug 16, 2024 | $0.81 |
| Aug 19, 2024 | $0.81 |
| Aug 20, 2024 | $0.81 |
| Aug 21, 2024 | $0.764 |
| Aug 22, 2024 | $0.760 |
| Aug 23, 2024 | $0.760 |
| Aug 26, 2024 | $0.700 |
| Aug 27, 2024 | $0.716 |
| 4 days before | -5.41% |
| 4 days after | -6.35% |
| On release day | -0.563% |
| Change in period | -11.42% |
| Release date | Feb 20, 2025 |
| Price on release | $0.760 |
| EPS estimate | - |
| EPS actual | $0.0224 |
| Date | Price |
|---|---|
| Feb 13, 2025 | $0.734 |
| Feb 14, 2025 | $0.760 |
| Feb 18, 2025 | $0.760 |
| Feb 19, 2025 | $0.760 |
| Feb 20, 2025 | $0.760 |
| Feb 21, 2025 | $0.86 |
| Feb 24, 2025 | $0.84 |
| Feb 25, 2025 | $0.84 |
| Feb 26, 2025 | $0.84 |
| 4 days before | 3.55% |
| 4 days after | 10.53% |
| On release day | 19.44% |
| Change in period | 14.45% |
| Release date | Aug 17, 2025 |
| Price on release | $1.11 |
| EPS estimate | - |
| EPS actual | $0.0370 |
| Date | Price |
|---|---|
| Aug 11, 2025 | $1.10 |
| Aug 12, 2025 | $1.10 |
| Aug 13, 2025 | $1.10 |
| Aug 14, 2025 | $1.10 |
| Aug 15, 2025 | $1.11 |
| Aug 18, 2025 | $1.00 |
| Aug 19, 2025 | $1.00 |
| Aug 20, 2025 | $1.00 |
| Aug 21, 2025 | $1.00 |
| 4 days before | 0.91% |
| 4 days after | -9.91% |
| On release day | -9.91% |
| Change in period | -9.09% |
| Release date | Feb 18, 2026 |
| Price on release | $1.51 |
| EPS estimate | $0.0210 |
| EPS actual | $0.0256 |
| EPS surprise | 21.90% |
| Date | Price |
|---|---|
| Feb 11, 2026 | $1.51 |
| Feb 12, 2026 | $1.51 |
| Feb 13, 2026 | $1.51 |
| Feb 17, 2026 | $1.51 |
| Feb 18, 2026 | $1.51 |
| Feb 19, 2026 | $1.51 |
| Feb 20, 2026 | $1.51 |
| Feb 23, 2026 | $1.51 |
| Feb 24, 2026 | $1.51 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Cogstate Earnings Call Transcript Summary of Q4 2025
Cogstate reported a strong FY25 with revenue of AUD 53.1m (up 22% YoY) and Clinical Trials revenue of AUD 50.6m (up 28% YoY). Profit before tax rose to AUD 13.9m (up 96%) and profit after tax to AUD 10.1m (up 86%), with gross margin of 61%, EBITDA margin of 30% and EBIT margin of 25%. Cash flow from operations nearly doubled to AUD 11.5m and cash on hand was AUD 35.6m after a AUD 4.8m share buyback. The Board declared a maiden fully franked dividend of AUD 0.02 per share and set a trailing target payout ratio of 20–50% of NPAT. Key growth drivers are: (1) the Medidata partnership expanding commercial reach into additional CNS indications (42 open joint opportunities and early contract wins), (2) an increasing mix of higher‑margin software license revenue, (3) early commercialisation of AI-powered products expected in FY26, and (4) expansion into psychiatric/mood disorders (already AUD 4m of psychiatric awards in early FY26). Management highlighted ongoing investments in product, AI and data engineering which may cause a modest margin compression in FY26 depending on revenue growth, but they emphasised substantial operating leverage and multi-year margin upside as license revenue scales. Backlog/contracted revenue stood at approximately AUD 35.9m for FY26 at the time of the call, with AUD 14.1m of new contracts signed in the first weeks of FY26.
